El Sayed F, Bayle-Lebey P, Marguery M C, Bazex J
Service de Dermatologie, Vénéréologie et Allergologie, Hôpital Purpan, Toulouse.
Ann Dermatol Venereol. 1996;123(1):26-8.
Transdermal administration of drugs to obtain a systemic effect may lead to allergic sensitization and compromise subsequent use via another administration route.
A 52-year-old woman presented contact eczema with the transdermal therapeutic system Estraderm TTS50. Generalized eczema developed later after oral administration of an oestrogen derivative. Skin tests demonstrated allergic sensitization to 17 beta-oestradiol.
Contact eczema due to transdermal therapeutic systems are usually caused by agents other than the active drug. Sensitization to the active drug raises the risk of generalized eczema and subsequent systemic complications. This risk must be taken into account when prescribing substitution hormone therapy for menopause.
经皮给药以获得全身效应可能导致过敏致敏，并影响后续通过其他给药途径的使用。
一名52岁女性使用经皮治疗系统Estraderm TTS50后出现接触性湿疹。口服雌激素衍生物后，全身湿疹随后出现。皮肤试验显示对17β-雌二醇过敏致敏。
经皮治疗系统引起的接触性湿疹通常由活性药物以外的因素引起。对活性药物的致敏会增加全身湿疹和后续全身并发症的风险。在为更年期开替代激素治疗处方时，必须考虑到这种风险。
